The Utility of Plasma Fibrinopeptide Assays

• References

• 1 Nossel HL, Yudelman I, Canfield RE, Butler Jr VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
• 2 Holvoet P, Lijnen HR, Collen D. A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion. Blood 1986; 67: 1482-1487
• 3 Kockum C, Frebelius S. Rapid radioimmunoassay of human fibrinopeptide A - removal of cross-reacting fibrinogen with bentonite. Thromb Res 1980; 19: 589-598
• 4 Eckhardt T, Nossel HL, Hurlet Jensen A, LaGamma KS, Owen J, Auerbach M. Measurement of desarginine fibrinopeptide B in human blood. J Clin Invest 1981; 67: 809-816
• 5 Nichols AB, Owen J, Kaplan KL, Sciacca RR, Cannon PJ, Nossel HL. Fibrinopeptide A, platelet factor 4, and beta-thromboglobulin levels in coronary heart disease. Blood 1982; 60: 650-654
• 6 Leeksma OC, Meijer Huizinga F, Stoepman van Dalen EA, van Ginkel CJ, van Aken WG, van Mourik JA. Fibrinopeptide A and the phosphate content of fibrinogen in. venous thromboembolism and disseminated intravascular coagulation. Blood 1986; 67: 1460-1467
• 7 Koehn JA, Canfield RE. Purification of human fibrinopeptides by high-performance liquid chromatography. Anal Biochem 1981; 116: 349-356
• 8 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. A monoclonal antibody with ability to distinguish between NH₂-terminal fragments derived from fibrinogen and fibrin. Mol Immunol 1983; 20: 1191-1200
• 9 Canfield RE, Dean J, Nossel HL, Butler Jr VP, Wilner GD. Reactivity of fibrinogen and fibrinopeptide A containing fibrinogen fragments with antisera to fibrinopeptide A. Biochemistry 1976; 15: 1203-1209
• 10 Nossel HL, Butler Jr VP, Wilner GD, Canfield RE, Harfenist EJ. Specificity of antisera to human fibrinopeptide A used in clinical fibrinopeptide A assays. Thromb Haemostas 1976; 35: 101-109
• 11 Wilner GD, Nossel HL, Canfield RE, Butler Jr VP. Immunochemical studies of human fibrinopeptide A using synthetic peptide homologues. Biochemistry 1976; 15: 1209-1213
• 12 Bilezikian SB, Nossel HL. Unique pattern of fibrinogen cleavage by human leukocyte proteases. Blood 1977; 50: 21-28
• 13 Weitz JI, Landman SL, Crowley KA, Birken S, Morgan FJ. Development of an assay for in vivo neutrophil elastase activity. Increased elastase activity in patients with alpha-1-proteinase inhibitor deficiency. J Clin Invest 1986; 78: 155-162
• 14 Mombelli G, Roux A, Haeberli A, Straub PW. Comparison of ¹²⁵I- fibrinogen kinetics and fibrinopeptide A in patients with disseminated neoplasias. Blood 1982; 60: 381-388
• 15 Peuscher FW, Cleton FJ, Armstrong L, Stoepman van Dalen EA, Van Mourik JA, van Aken WG. Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. J Lab Clin Med 1980; 96: 5-14
• 16 Owen J, Friedman KD, Grossman B, Wilkins C, Berke AD, Powers ER. Quantitation of fragment X formation during thrombolytic therapy with streptokinase and with tissue plasminogen activator. J Clin Invest 1987; 79: 1642-1647
• 17 Alkjaersig N, Fletcher AP. Catabolism and excretion of fibrinopeptide A. Blood 1982; 60: 148-156